A software bill of materials (SBOM) is an inventory of software components and their relationships, including manufacturer-developed software, purchased or licensed components, open-source software and upstream dependencies. It helps identify devices potentially affected by vulnerabilities in those components. Machine-readable, industry-accepted formats support automated analysis; CycloneDX and SPDX are common examples. An SBOM does not by itself prove that a component is secure or that a vulnerability is exploitable in a particular device.

Why it matters

MedTech teams can generate an SBOM during software builds, review it when shipped software changes, and use it in vulnerability monitoring. VEX can add product-specific exploitability context but does not replace the inventory or risk assessment. Information sharing with healthcare operators should follow the device's labeling, security communication plan and applicable agreements; an SBOM alone is not a universal hospital procurement guarantee.

Common pitfalls

•Omitting third-party components or upstream dependencies.
•Treating a machine-readable format recommendation as the wording of the statute.
•Assuming an inventory proves that software has no vulnerabilities.
•Failing to update component information when marketed software changes.

Sources

Section 524B of the FD&C Act · FDA
CISA SBOM Resources & Minimum Elements · CISA
CycloneDX Specification · OWASP
SPDX Specification (ISO/IEC 5962:2021) · Linux Foundation
FDA guidance publication page: February 3, 2026 edition and superseded guidance · FDA
FDA final cybersecurity guidance, February 3, 2026 · US official source

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.